|
1
|
Mahecha AM and Wang H: The influence of
vascular endothelial growth factor-A and matrix metalloproteinase-2
and −9 in angiogenesis, metastasis, and prognosis of endometrial
cancer. Onco Targets Ther. 10:4617–4624. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ray M and Fleming G: Management of
advanced-stage and recurrent endometrial cancer. Semin Oncol.
36:145–154. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Davidson BA, Foote J, Clark LH, Broadwater
G, Ehrisman J, Gehrig P, Graybill W, Alvarez Secord A and
Havrilesky LJ: Tumor grade and chemotherapy response in
endometrioid endometrial cancer. Gynecol Oncol Rep. 17:3–6. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen HX, Xu XX, Tan BZ, Zhang Z and Zhou
XD: MicroRNA-29b inhibits angiogenesis by targeting VEGFA through
the MAPK/ERK and PI3K/Akt signaling pathways in endometrial
carcinoma. Cell Physiol Biochem. 41:933–946. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pasquinelli AE: MicroRNAs and their
targets: Recognition, regulation and an emerging reciprocal
relationship. Nat Rev Genet. 13:271–282. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Krist B, Florczyk U,
Pietraszek-Gremplewicz K, Jozkowicz A and Dulak J: The Role of
miR-378a in metabolism, angiogenesis, and muscle biology. Int J
Endocrinol. 2015:2817562015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Srivastava AK, Banerjee A, Cui T, Han C,
Cai S, Liu L, Wu D, Cui R, Li Z, Zhang X, et al: Inhibition of
miR-328-3p impairs cancer stem cell function and prevents
metastasis in ovarian cancer. Cancer Res. 79:2314–2326. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kouri FM, Hurley LA, Daniel WL, Day ES,
Hua Y, Hao L, Peng CY, Merkel TJ, Queisser MA, Ritner C, et al:
miR-182 integrates apoptosis, growth, and differentiation programs
in glioblastoma. Genes Dev. 29:732–745. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang FB, Du Y, Tian Y, Ji ZG and Yang PQ:
miR-1299 functions as a tumor suppressor to inhibit the
proliferation and metastasis of prostate cancer by targeting NEK2.
Eur Rev Med Pharmacol Sci. 23:530–538. 2019.PubMed/NCBI
|
|
10
|
Peng H, Wang L, Su Q, Yi K, Du J and Wang
Z: miR-31-5p promotes the cell growth, migration and invasion of
colorectal cancer cells by targeting NUMB. Biomed Pharmacother.
109:208–216. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhen Z, Dong F, Shen H, Wang QG, Yang L
and Hu J: miR-524 inhibits cell proliferation and induces cell
apoptosis in thyroid cancer via targeting SPAG9. Eur Rev Med
Pharmacol Sci. 22:3812–3818. 2018.PubMed/NCBI
|
|
12
|
Zheng X, Xu K, Zhu L, Mao M, Zhang F and
Cui L: miR-486-5p Act as a biomarker in endometrial carcinoma:
Promotes cell proliferation, migration, invasion by targeting
MARK1. Onco Targets Ther. 13:4843–4853. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang C and Liu B: miR-101-3p induces
autophagy in endometrial carcinoma cells by targeting EZH2. Arch
Gynecol Obstet. 297:1539–1548. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang HC, Han YY, Zhang XM, Xiao N, Jiang
T, Zhu S, Wang EP and Chen CB: miR-522 facilitates the prosperities
of endometrial carcinoma cells by directly binding to monoamine
oxidase B. Kaohsiung J Med Sci. 35:598–606. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sales CB, Buim ME, de Souza RO, de Faro
Valverde L, Mathias Machado MC, Reis MG, Soares FA, Ramos EA and
Gurgel Rocha CA: Elevated VEGFA mRNA levels in oral squamous cell
carcinomas and tumor margins: A preliminary study. J Oral Pathol
Med. 45:481–485. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Claesson-Welsh L and Welsh M: VEGFA and
tumour angiogenesis. J Intern Med. 273:114–127. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Peng T, Li Z, Li D and Wang S: MACC1
promotes angiogenesis in cholangiocarcinoma by upregulating VEGFA.
Onco Targets Ther. 12:1893–1903. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Horwitz E, Stein I, Andreozzi M, Nemeth J,
Shoham A, Pappo O, Schweitzer N, Tornillo L, Kanarek N, Quagliata
L, et al: Human and mouse VEGFA-amplified hepatocellular carcinomas
are highly sensitive to sorafenib treatment. Cancer Discov.
4:730–743. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Luo X and Feng GS: VEGFA genomic
amplification tailors treatment of HCCs with sorafenib. Cancer
Discov. 4:640–641. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen X, Xu X, Pan B, Zeng K, Xu M, Liu X,
He B, Pan Y, Sun H and Wang S: miR-150-5p suppresses tumor
progression by targeting VEGFA in colorectal cancer. Aging (Albany
NY). 10:3421–3437. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guset G, Costi S, Lazar E, Dema A,
Cornianu M, Vernic C and Păiuşan L: Expression of vascular
endothelial growth factor (VEGF) and assessment of microvascular
density with CD34 as prognostic markers for endometrial carcinoma.
Rom J Morphol Embryol. 51:677–682. 2010.PubMed/NCBI
|
|
22
|
Panda H, Pelakh L, Chuang TD, Luo X,
Bukulmez O and Chegini N: Endometrial miR-200c is altered during
transformation into cancerous states and targets the expression of
ZEBs, VEGFA, FLT1, IKKβ, KLF9, and FBLN5. Reprod Sci. 19:786–796.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Garcia DM, Baek D, Shin C, Bell GW,
Grimson A and Bartel DP: Weak seed-pairing stability and high
target-site abundance decrease the proficiency of lsy-6 and other
microRNAs. Nat Struct Mol Biol. 18:1139–1146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Grimson A, Farh KK, Johnston WK,
Garrett-Engele P, Lim LP and Bartel DP: MicroRNA targeting
specificity in mammals: Determinants beyond seed pairing. Mol Cell.
27:91–105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
SGO Clinical Practice Endometrial Cancer
Working Group, ; Burke WM, Orr J, Leitao M, Salom E, Gehrig P,
Olawaiye AB, Brewer M, Boruta D, Villella J, et al: Endometrial
cancer: A review and current management strategies: Part I. Gynecol
Oncol. 134:385–392. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang CH, Zhang XY, Zhou LN, Wan Y, Song
LL, Gu WL, Liu R, Ma YN, Meng HR, Tian YL and Zhang Y: LncRNA SNHG8
participates in the development of endometrial carcinoma through
regulating c-MET expression by miR-152. Eur Rev Med Pharmacol Sci.
22:1629–1637. 2018.PubMed/NCBI
|
|
28
|
Teague EM, Print CG and Hull ML: The role
of microRNAs in endometriosis and associated reproductive
conditions. Hum Reprod Update. 16:142–165. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lamouille S, Connolly E, Smyth JW, Akhurst
RJ and Derynck R: TGF-β-induced activation of mTOR complex 2 drives
epithelial-mesenchymal transition and cell invasion. J Cell Sci.
125:1259–1273. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bullock MD, Sayan AE, Packham GK and
Mirnezami AH: MicroRNAs: Critical regulators of epithelial to
mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in
cancer progression. Biol Cell. 104:3–12. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nusse R and Clevers H: Wnt/beta-catenin
signaling, disease, and emerging therapeutic modalities. Cell.
169:985–999. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Majidinia M, Aghazadeh J,
Jahanban-Esfahlani R and Yousefi B: The roles of Wnt/beta-catenin
pathway in tissue development and regenerative medicine. J Cell
Physiol. 233:5598–5612. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shen YN, He HG, Shi Y, Cao J, Yuan JY,
Wang ZC, Shi CF, Zhu N, Wei YP, Liu F, et al: Kruppel-like factor 8
promotes cancer stem cell-like traits in hepatocellular carcinoma
through Wnt/β-catenin signaling. Mol Carcinog. 56:751–760. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shen Q, He T and Yuan H: Hsa_circ_0002577
promotes endometrial carcinoma progression via regulating
miR-197/CTNND1 axis and activating Wnt/β-catenin pathway. Cell
Cycle. 18:1229–1240. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Park SA, Kim LK, Kim YT, Heo TH and Kim
HJ: Long non-coding RNA steroid receptor activator promotes the
progression of endometrial cancer via Wnt/β-catenin signaling
pathway. Int J Biol Sci. 16:99–115. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen P, Xing T, Wang Q, Liu A, Liu H, Hu
Y, Ji Y, Song Y and Wang D: MicroRNA-202 inhibits cell migration
and invasion through targeting FGF2 and inactivating Wnt/β-catenin
signaling in endometrial carcinoma. Biosci Rep. 39:BSR201906802019.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kontos CK, Tsiakanikas P, Avgeris M,
Papadopoulos IN and Scorilas A: miR-15a-5p, A novel prognostic
biomarker, predicting recurrent colorectal adenocarcinoma. Mol
Diagn Ther. 21:453–464. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Long J, Jiang C, Liu B, Fang S and Kuang
M: MicroRNA-15a-5p suppresses cancer proliferation and division in
human hepatocellular carcinoma by targeting BDNF. Tumour Biol.
37:5821–5828. 2016. View Article : Google Scholar : PubMed/NCBI
|
